The study, published in BMC Cancer, was led by Cui Meng and Hong Su, with Yanfeng Xi of Shanxi Province Cancer Hospital as corresponding author. The team set out to answer a deceptively simple question: if R-loops are master regulators of genome stability, can the genes that control them be woven into a score that tells clinicians something meaningful about an individual patient’s disease? To do this, they compiled a curated list of R-loop-related genes and cross-referenced it against bulk transcriptomic data and single-cell RNA sequencing datasets from patients with esophageal squamous cell carcinoma, the dominant form of esophageal cancer in East Asia and a histological subtype notorious for late diagnosis and five-year survival rates that remain grim even after decades of effort.

Using a battery of bioinformatic algorithms, the researchers distilled the R-loop-related gene landscape down to seven genes that tracked with patient prognosis. Within that set, three emerged as core players: BRIX1, CHEK1, and NUP155. Each of these genes has a plausible biochemical connection to the R-loop world. CHEK1, also known as Chk1, is a checkpoint kinase that pauses the cell cycle when DNA damage is detected, buying time for repair machinery that must contend with RNA-DNA hybrids at replication forks. BRIX1 participates in ribosome biogenesis, a process that generates enormous transcriptional traffic through repetitive ribosomal DNA and is a well-known hotspot for R-loop formation. NUP155 encodes a component of the nuclear pore complex, the gateway that coordinates traffic between the nucleus and cytoplasm and increasingly appears to influence genome architecture and transcription itself.

Crucially, the team did not stop at computational predictions. They validated their findings in the laboratory using reverse transcription quantitative polymerase chain reaction, Western blotting, immunohistochemistry, and immunofluorescence on patient tissue samples. All three core genes were significantly upregulated in esophageal squamous cell carcinoma tissues compared with adjacent non-tumor controls, confirming that the computational signal reflected genuine molecular changes in the tumors themselves. The work was approved by the Shanxi Provincial Tumor Hospital Institutional Ethics Committee, and written informed consent was obtained from all participants, grounding the molecular story in ethically sourced human material.

Pathway analysis added another layer of coherence to the picture. BRIX1, CHEK1, and NUP155 were co-enriched in DNA replication, pyrimidine metabolism, RNA degradation, and MYC target pathways. That convergence matters because each of these processes is intimately tied to R-loop biology. Rapid DNA replication leaves little slack for resolving RNA-DNA hybrids that form behind the transcription machinery; pyrimidine metabolism governs the nucleotide supply that feeds both DNA and RNA synthesis; RNA degradation pathways clear away transcripts that would otherwise invade the genome; and MYC, one of the most notorious oncogenes, drives the hypertranscription that makes cancer cells especially prone to R-loop accumulation. The authors suggest this points to potential crosstalk between the three genes and broader R-loop regulatory networks, though they are careful to note that functional validation remains a task for future studies.

Perhaps the most clinically striking result came when the researchers split patients into groups based on their R-loop-related gene score. Counterintuitively, patients in the low-score group had significantly worse overall survival. Yet when the team interrogated the tumor immune microenvironment of those low-scoring patients, they found something paradoxical: an immune landscape that appeared more active but also more dysfunctional. In other words, the tumors were crowded with immune cells, but those cells seemed unable to mount an effective anti-tumor response. This kind of immune activation without immune success is a familiar frustration in oncology, and it hints that R-loop biology may help determine whether the immune system’s presence inside a tumor translates into immune system’s victory over it.

To dig deeper into where the R-loop signal actually originates within the tumor, the researchers turned to single-cell RNA sequencing, which resolves gene expression cell by cell rather than averaging across a whole tissue. Applying five independent algorithms, they consistently identified squamous epithelium cells as the cell type carrying the highest R-loop-related gene scores. This is a biologically satisfying result, since esophageal squamous cell carcinoma arises from precisely these epithelial cells, and it suggests that the R-loop signature is not merely a bystander effect of infiltrating immune or stromal cells but is written into the malignant cells themselves.

Within the malignant squamous epithelium population, cells with high R-loop-related gene scores showed two defining features. First, they displayed enhanced stemness, a measure of how closely a cell resembles stem-like progenitors that can self-renew and seed new tumor growth. Stemness is strongly associated with treatment resistance and relapse, so a molecular signature that flags it could help identify patients at risk of aggressive disease. Second, these high-scoring cells showed activation of the JAK-STAT signaling pathway, hypoxia programs, and DNA repair pathways. The combination is telling: hypoxic tumors are notoriously resistant to both radiation and immunotherapy, JAK-STAT signaling shapes how cells respond to inflammatory cues, and heightened DNA repair activity can blunt the effect of DNA-damaging chemotherapy.

The study also explored drug sensitivity relationships for the core genes, generating a resource that could guide the selection of existing compounds for further testing. CHEK1 in particular is already the target of inhibitor programs in the pharmaceutical industry, given its role in checkpoint control, and the new data suggest that patients whose tumors score high on the R-loop signature might be candidates for such approaches. The authors emphasize, however, that these are hypotheses generated by computational analysis and laboratory correlation, not proof of therapeutic benefit, and that functional experiments will be needed before any of this reaches the clinic.

What makes this work notable is its scope rather than any single finding. By integrating bulk transcriptomics, single-cell resolution data, experimental validation in patient tissues, and immune microenvironment profiling, the team has produced the first systematic characterization of the R-loop landscape in esophageal squamous cell carcinoma. The seven-gene signature offers a potential prognostic biomarker, the identification of squamous epithelium cells as the R-loop hotspot points to the cellular origin of the phenomenon, and the paradoxical immune findings open a new angle on why some esophageal tumors resist immunotherapy despite heavy immune infiltration. The researchers caution that their scoring system requires prospective validation in independent cohorts and that the biology linking R-loops to immune dysfunction remains to be worked out experimentally. Still, for a disease with such poor outcomes and such a stubbornly unclear pathogenesis, the study reframes an old molecular curiosity, the RNA-DNA hybrid, as a promising new lens through which to view prognosis, tumor stemness, and the immune battlefield inside the esophageal tumor.

Subject of Research: R-loop-related gene signatures as prognostic and immune microenvironment markers in esophageal squamous cell carcinoma

Article Title: An R-loop-related gene signature predicts prognosis and shapes the immune microenvironment in esophageal squamous cell carcinoma

Article References: Meng, C., Su, H., Yan, R., Sun, R., Yu, Q., Meng, Y., & Xi, Y. (2026). An R-loop-related gene signature predicts prognosis and shapes the immune microenvironment in esophageal squamous cell carcinoma. BMC Cancer. https://doi.org/10.1186/s12885-026-16564-4

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16564-4

Keywords: esophageal squamous cell carcinoma, R-loops, gene signature, BRIX1, CHEK1, NUP155, tumor microenvironment, cancer stemness, single-cell RNA sequencing, prognosis, DNA repair, immunotherapy resistance

The researchers set out to close a major gap in kinome pharmacology. Protein kinases—the 518 enzymes that phosphorylate most human proteins and orchestrate nearly every cellular process—are not merely catalytic cores. Beyond their conserved kinase domains, they carry additional domains that mediate autoinhibition, subcellular localization, and complex formation. Autoinhibitory domains (AIDs) typically keep kinases dormant by docking onto the kinase domain and masking the ATP-binding site, blocking both enzymatic activity and substrate interactions until an activating signal relieves this restraint. Classical structural methods struggle to characterize these domains because many AIDs are intrinsically disordered or connected to the catalytic core through flexible linkers, and most structural studies rely on truncated, purified recombinant proteins that lack the physiological post-translational modifications and binding partners essential for correct function. Whether ATP-competitive inhibitors, which stabilize the active DFG-in conformation of the kinase domain, also force structural changes at the AID remained a poorly explored dark space.

To address this, the team developed a multimodal proteomics strategy combining three complementary mass spectrometry-based approaches. The first, AP-LiP-MS, applies limited proteolysis coupled to mass spectrometry on affinity-purified samples: kinases are purified from human cells under native conditions, treated with an inhibitor, and then exposed to proteinase K, which preferentially cleaves accessible and flexible regions. Changes in the resulting conformation-specific peptide fragments reveal structural shifts with high sequence coverage while preserving the native cellular context. This structural readout was paired with contextual proteomics—affinity purification mass spectrometry (AP-MS) to measure complex formation and in vivo proximity labeling using the miniTurbo biotin ligase to map the kinase’s biochemical neighborhood in living cells. The approach was first benchmarked on the kinase DCLK1, where known X-ray crystal structures of the autoinhibited and inhibitor-bound states confirmed that AP-LiP-MS faithfully detects the anticipated structural rearrangements.

Applying the workflow to three disease-associated kinases with well-characterized ATP-competitive inhibitors—CAMKK2 targeted by SGC-CAMKK2-1, CHEK1 targeted by rabusertib, and PRKCA targeted by Gö 6983—the researchers found a striking common theme. In every case, inhibitor binding produced structural changes precisely at the autoinhibitory domain, with increased proteinase K susceptibility indicating that the AID becomes more solvent-exposed. This is consistent with the AID dissociating from the kinase domain, driving the inhibited enzyme into an open, active-like conformation that mimics the structural unlocking that occurs during normal kinase activation. Notably, a structurally similar negative control compound that does not bind CAMKK2 induced neither structural nor interaction changes, confirming the specificity of the observations. For PRKCA, structural alterations extended into the membrane-binding C2 domain, specifically at a short regulatory segment associated with autoinhibition, hinting that multiple domain-domain interactions are disrupted by drug binding.

The consequences of these conformational shifts proved to be as diverse as they were unexpected. For CAMKK2, the inhibitor stabilized a complex between CAMKK2 and PRKAA1, the catalytic subunit of the AMPK energy-sensing complex. Catalytically inactive and autonomously active CAMKK2 mutants responded to the drug with the same interaction pattern, demonstrating that the effect depends on the conformational change rather than on catalytic inhibition. Structural modeling with AlphaFold3 suggested that the activation-relevant T183 residue of PRKAA1 becomes buried within the predicted CAMKK2–PRKAA1 interface. Functional experiments confirmed the implication: in glucose-starved cells, SGC-CAMKK2-1 reduced T183 phosphorylation of PRKAA1 by upstream kinases such as LKB1, and this suppression was rescued when CAMKK2 was depleted by siRNA. In other words, the inhibited kinase acts as a physical shield that sequesters AMPK and blocks its activation through an entirely non-catalytic, scaffolding mechanism—potentially shutting down both the calcium-dependent and energy-stress branches of AMPK signaling simultaneously.

Strikingly, a disease-associated CAMKK2 variant, the R311C mutation found in a patient with bipolar disorder, completely abolished the inhibitor-induced interaction with PRKAA1. Because R311 faces the predicted interaction interface while the neighboring catalytic residue D312 lies outside it, the finding offers the first mechanistic clue for how this genetic variant may uncouple the CAMKK2–AMPK signaling axis in patients, and it underscores that drug responses can depend critically on the specific disease variant a patient carries—a consideration for personalized medicine.

The second model kinase, CHEK1, revealed a different flavor of paradox. Rabusertib remodeled CHEK1’s interactions with numerous DNA-damage response proteins, increasing binding to 14-3-3 proteins, the deubiquitylating enzyme USP7, PCNA, and MCM replication licensing factors, and elevating phosphorylation at the ATR-targeted S317 site—changes mirroring those seen during genuine DNA damage-induced activation. The single interactor that dissociated was CLPB, a mitochondrial protein previously identified in multiple studies as a CHEK1 partner. CLPB dissociation occurred in both wild-type and catalytically inactive CHEK1 but not in a constitutively open mutant, again implicating the conformational rather than catalytic consequence of inhibition. Because CLPB loss is known to cause mitochondrial fragmentation, the researchers examined mitochondrial morphology by super-resolution microscopy. Rabusertib treatment significantly increased mitochondrial fragmentation, an effect that persisted even when the canonical CDK1–DRP1 fragmentation pathway was blocked with the CDK1 inhibitor RO-3306, and that could not be reproduced by DNA damage alone. While a direct causal link between CHEK1–CLPB dissociation and fragmentation remains to be established, the data suggest that CHEK1 inhibition may disrupt mitochondrial proteostasis through a mechanism independent of the drug’s intended catalytic target.

The third model, PRKCA, demonstrated how inhibitor-induced structural changes can redirect a kinase within the cell. Upon Gö 6983 binding, proximity labeling revealed a rapid shift of PRKCA toward membrane-associated proteins at cell junctions, including tight junction, adherens junction, and desmosome components, as well as the known interactor integrin beta-1. Calcium imaging ruled out changes in intracellular calcium as the driver, and a dose-response experiment showed that these junctional proximity changes occurred at significantly lower drug concentrations than other effects, consistent with a specific on-target mechanism. Catalytically inactive and constitutively active PRKCA mutants responded identically, confirming the phenotype is independent of catalytic inhibition. Live-cell imaging of EGFP-tagged PRKCA captured the kinase relocating to the cell periphery—particularly cell-cell contact sites—within eight minutes of drug addition. The researchers propose that Gö 6983 binding opens the C2 domain, exposing a lysine cluster that can bind the junctional lipid PIP2, thereby recruiting the inhibited kinase to membranes through a calcium-independent route.

Taken together, the study establishes the ATP-binding site as a major organizing center of kinase conformation and interaction, and suggests that inhibitor-induced non-catalytic gain-of-function is likely far more prevalent among kinases with autoinhibitory domains than currently appreciated. The authors point to existing examples such as the JAK2 inhibitor ruxolitinib, which paradoxically primes JAK2 hyperphosphorylation and contributes to side effects after drug withdrawal, and BRAF inhibitors that allosterically promote RAF dimerization and MAPK activation, as evidence that such mechanisms already matter clinically. Because many AID-mediated effects would be missed by conventional target engagement assays focused on catalytic kinetics, the authors advocate for systematic multimodal proteomic profiling of both wild-type and disease-mutant kinases during early drug development. The combination of structural and contextual proteomics is not restricted to kinases and could extend to targets lacking catalytic activity altogether. By mapping inhibitor-modulated conformational and interactome landscapes early, researchers hope to detect unexpected liabilities before they surface in the clinic, ultimately guiding the design of safer and more effective kinase-targeted therapeutics.

Subject of Research: Inhibitor-induced displacement of kinase autoinhibitory domains driving non-catalytic drug effects

Article Title: Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains

Article References: Reber, V., Keller, S., Loosli, S. A., Arima, Y., Kleele, T., Picotti, P., & Gstaiger, M. (2026). Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains. Molecular Systems Biology, 22(9), 1474-1500. https://doi.org/10.1038/s44320-026-00229-2

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00229-2

Keywords: kinase inhibitors, autoinhibitory domains, proteomics, protein-protein interactions, CAMKK2, CHEK1, PRKCA, AMPK, mitochondrial fragmentation, drug mechanisms, conformational change, Molecular Systems Biology